drugset / Trial / NCT04084158
A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
Phase 2
Suspended
100 enrolled
Zhejiang Cancer Hospital
Shanghai Junshi Bioscience Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to explore the efficacy and safety of Toripalimab injection (JS001) given before and after concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
Timeline
- Start
- 2019-09-07
- Primary completion
- 2021-12-30
- Completion
- 2021-12-30
Outcome
Outcome not reported
Stopped: “combination arm delevelped significant poor prognosis”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Toripalimab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Background | Carboplatin | Small molecule | 2 unknown | Intravenous |
| Background | Carboplatin | Small molecule | 6 unknown | Intravenous |
| Background | Paclitaxel | Small molecule | 60 mg/m2 | Intravenous |
| Background | Paclitaxel | Small molecule | 260 mg/m2 | Intravenous |